NEW YORK, April 30, 2026 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Theravance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 3, 2026, Theravance issued a press release “announc[ing] topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare disease.” Theravance disclosed that “[t]he study did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score” and “[a]s a result of this outcome, the Company has decided to wind down the ampreloxetine program.”
On this news, Theravance’s stock price fell $4.99 per share, or 26.33%, to close at $13.96 per share on March 3, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc—tbph-302759717.html
SOURCE Pomerantz LLP
